JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
FDA Feedback 'Best Case Scenario' for Sarepta Therapeutic (SRPT), Baird Said; PT Lifted
April 21, 2014 3:41 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $35 to $53 calling the FDA feedback the 'best case scenario.'
Skorney said, "The final FDA minutes reflected several positive outcomes: 1) validation of a historically controlled... More
UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to Buy
April 21, 2014 1:25 PM EDT(Updated - April 21, 2014 1:55 PM EDT)
Canaccord Genuity upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Hold to Buy with a price target of $63.00. Earlier Sarepta announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014. The plan to submit an NDA for eteplirsen by the end of 2014... More
William Blair Upgrades Sarepta Therapeutic (SRPT) to Outperform (Earlier)
April 21, 2014 11:10 AM EDTWilliam Blair upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $63.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $24.40 yesterday.
... MoreSarepta Therapeutic (SRPT) Target Ratcheted Higher at Needham & Company
April 21, 2014 10:49 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $36 to $52 after a path to accelerated approval of was reached with the FDA.
"Based on a guidance letter recently... More
Sarepta (SRPT) Plans to Submit NDA for Eteplirsen by End of 2014
April 21, 2014 6:57 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Eteplirsen is Sareptas lead exon-skipping drug candidate in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.
The plan to submit an NDA for eteplirsen by the end of 2014 is based on a guidance letter from... More
